|
Haleon PLC on Wednesday reported increased quarterly revenue and reiterated its growth forecasts for the year. The Surrey, England-based consumer healthcare company’s revenue increased 0.1% to £2.86 billion in the first quarter of 2026 from £2.85 billion the year before. On an organic basis, annual revenue growth was 2.2%, Haleon said, compared with a 3.5% growth rate in the first quarter of 2025. The North America segment delivered 1.0% organic revenue growth, ‘despite a weak cold and flu season with growth initiatives progressing well’. However, revenue fell 4.9% at reported currency rates to £932 million from £980 million. ‘We delivered a competitive performance in a challenging market, with North America returning to growth and Oral Health again performing strongly, with innovation and geographic expansion driving double-digit rowth in Sensodyne and parodontax,’ Chief Executive Officer Brian McNamara commented. ‘This was tempered by a weak cold and flu season.’ EMEA & LatAm revenue rose 4.4%, or 2.1% organically, to £1.24 billion. Haleon said this ‘reflected a weaker macro-economic backdrop and performance in Brazil, and soft cold and flu season in APAC and Central & Eastern Europe.’ APAC revenue was flat, but grew 4.0% organically, at £685 million. Oral Health revenue climbed 5.9%, with 8.3% organic growth, to £932 million. Haleon said the ongoing ‘strong momentum’ was driven by its Sensodyne and parodontax products. However, Pain Relief revenue decreased 0.3% organically and 1.1% at reported rates to £654 million, while Respiratory Health revenue fell 5.0% to £499 million with a 3.4% organic decline. ‘We continue to make progress against our other strategic priorities, with our productivity initiatives driving strong gross margin improvement,’ CEO McNamara said. Haleon reaffirmed its guidance for 2026, forecasting organic revenue growth between 3% and 5%. It also expects high-single-digit percentage constant currency growth in adjusted operating profit. ‘Looking ahead, while we continue to navigate global geopolitical and macroeconomic uncertainties, we expect growth to accelerate across the balance of the year and remain on track to deliver on our FY guidance,’ McNamara said. Shares in Haleon opened higher but were down 3.3% at 339.40 pence late Wednesday morning in London. The wider FTSE 100 index was down 0.6%. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
